Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues

Estefania Burgos-Morón, Zaida Abad-Jiménez, Aranzazu Martínez de Marañón, Francesca Iannantuoni, Irene Escribano-López, Sandra López-Domènech, Christian Salom, Ana Jover, Vicente Mora, Ildefonso Roldan, Eva Solá, Milagros Rocha, Víctor M Víctor, Estefania Burgos-Morón, Zaida Abad-Jiménez, Aranzazu Martínez de Marañón, Francesca Iannantuoni, Irene Escribano-López, Sandra López-Domènech, Christian Salom, Ana Jover, Vicente Mora, Ildefonso Roldan, Eva Solá, Milagros Rocha, Víctor M Víctor

Abstract

Type 2 diabetes (T2D) is a metabolic disorder characterized by hyperglycemia and insulin resistance in which oxidative stress is thought to be a primary cause. Considering that mitochondria are the main source of ROS, we have set out to provide a general overview on how oxidative stress is generated and related to T2D. Enhanced generation of reactive oxygen species (ROS) and oxidative stress occurs in mitochondria as a consequence of an overload of glucose and oxidative phosphorylation. Endoplasmic reticulum (ER) stress plays an important role in oxidative stress, as it is also a source of ROS. The tight interconnection between both organelles through mitochondrial-associated membranes (MAMs) means that the ROS generated in mitochondria promote ER stress. Therefore, a state of stress and mitochondrial dysfunction are consequences of this vicious cycle. The implication of mitochondria in insulin release and the exposure of pancreatic β-cells to hyperglycemia make them especially susceptible to oxidative stress and mitochondrial dysfunction. In fact, crosstalk between both mechanisms is related with alterations in glucose homeostasis and can lead to the diabetes-associated insulin-resistance status. In the present review, we discuss the current knowledge of the relationship between oxidative stress, mitochondria, ER stress, inflammation, and lipotoxicity in T2D.

Keywords: ER stress; ROS; antioxidants; insulin resistance; mitochondria; oxidative stress; type 2 diabetes.

Conflict of interest statement

References

Figures

Figure 1
Figure 1
Mitochondrial superoxide (O2•−) generation by the electron transport chain (ETC) and the implication of the enzyme manganese superoxide dismutase (MnSOD), the only superoxide dismutase enzyme located in the mitochondrial matrix, in its detoxification. The elevated levels of O2•− induce damage to macromolecules, including lipids, proteins, and nucleic acids, and promote mitochondrial dysfunction. Absence of histones in mitochondrial DNA (mtDNA) and limited DNA repair mechanisms make mitochondria highly susceptible to DNA damage induced by O2•−. ADP: Adenoxine diphosphate; ATP: Adenosine triphosphate; GPX: Glutathione peroxidase; H2O2: Hydrogen peroxide; IMM: Inner mitochondrial membrane; IMS: Intermembrane space; O2•−: Superoxide anion; OH•: Hydroxyl radical; TRX: Thioredoxin reductase.
Figure 2
Figure 2
Oxidative protein machinery and ER stress. During disulfide bond formation, two electrons are transferred to the pair of cysteines in the polypeptide by the PDI active site. Thereafter, reduced PDI receive electrons from O2 through ERO1-mediated redox reaction, resulting in H2O2 formation. The GSH/GSSG system then recovers the redox status by scavenging H2O2. Several stimuli including increased protein synthesis demand overwhelm ER-folding capacity and disturb redox balance, leading to the accumulation of misfolded proteins and triggering ER stress. ER: Endoplasmic reticulum; ERO1: ER oxidoreductin 1; FFA: Free fatty acids; GSH: Glutathione; GSSG: Glutathione disulphide; NADPH: Nicotinamide adenine dinucleotide phosphate; PDI: Protein disulfide isomerase.
Figure 3
Figure 3
Cellular mechanisms in pancreatic β-cells involving mitochondrial ROS generation and their implication in insulin release and diabetes onset. (A) Mechanism of insulin release in β-cells in normal conditions. (B) Impaired insulin release by β-cells under hyperglycemic conditions. High glucose concentration in blood implies high ROS generation by mitochondria leading to alterations in insulin release. (C) Scheme of how hyperglycemia promotes ROS generation by ETC (electron transport chain) in mitochondria inducing oxidative stress. Oxidative stress is boosted by the ER stress as consequence of the accumulation of unfolded insulin peptides due to the enhanced demand of this hormone. In addition, the implication of Ca2+ ions from ER as a factor that increases ROS in mitochondria and the interconnection of both organelles through MAM (mitochondria-associated ER membranes) are depicted. ATP: Adenosine triphosphate; ER: Endoplasmic reticulum; GLUT2: Glucose transporter-2; ROS: Reactive oxygen species.
Figure 4
Figure 4
Development of insulin resistance and the relevant role of mitochondrial ROS generation. Frequent hyperglycemia condition promotes ROS production by mitochondria through the ETC. ER function and folding capacity is affected by mitochondrial ROS production. This process is especially important in pancreatic β-cells, in charge of insulin production and secretion. Initially, excess nutrient overload increases insulin synthesis demand. Perpetuated hyperglycemia and hyperinsulinemia progress to insulin resistance in peripheral tissues. This fact forces β-cells to produce more insulin promoting ER stress, in parallel with increased oxidative stress and mitochondrial dysfunction. Oxidative stress in mitochondria and ER stress feedback each other directly through ROS and also indirectly (curve arrow), aggravating the oxidative stress and promoting further insulin resistance. This situation can progress to β-cell failure and the impairment of insulin release, thus provoking the inability to control glucose levels in blood characteristic of T2D patients. Insulin resistance is also associated with processes such to inflammation, lipotoxicity, and autophagy impairment that make oxidative stress and insulin resistance characteristic of T2D worse. ETC: Electron transport chain; ER: Endoplasmic reticulum; FFA: Free fatty acids; ROS: Radical oxygen species.
Figure 5
Figure 5
Mechanisms of ROS-induced endothelial dysfunction in response to hyperglycemia. Vascular damage caused by elevated glucose levels is mainly derived by an imbalance between ROS production and NO bioavailability in the endothelium and by the direct damaged caused by the accumulation of AGE. Resulting endothelial dysfunction is characterized by the activation of several deleterious mechanisms, including proinflammatory response, recruitment of leukocytes, accumulation of oxidized LDL particles and impaired vasodilatation, in the onset of cardiovascular complications. AGE: Advanced glycation end-products; eNOS: Endothelial nitric oxide synthase; LDL: Low density lipoprotein particles; NADPHox: Nicotinamide adenine dinucleotide phosphate oxidase; NO: Nitric oxide; O2•−: Superoxide anion; ONOO−: Peroxynitrite; PKC: Protein kinase C; RNS: Radical nitrogen species.
Figure 6
Figure 6
Under insulin resistance condition, adipocytes are not able to respond to insulin stimuli and downregulate lipolysis. In this way, an uncontrolled release of FFA causes ectopic lipid deposition in body tissues and an augment of lipid intermediates derivate from metabolism (DAG and AcylCoA), which together lead to lipotoxicity and further insulin resistance. On the other hand, FFA are not fully processed by mitochondria triggering incomplete β-oxidation of them, further ROS production and oxidative stress. Finally, lipotoxicity and oxidative stress they both concur to alterations in cells homeostasis and β-cells failure. AcylCoA: Acetyl coenzyme A; DAG: Dyacylglicerol; FFA: Free fatty acids; IR: Insulin resistance; ROS: Radical oxygen species.

References

    1. Cho N.H., Shaw J.E., Karuranga S., Huang Y., da Rocha Fernandes J.D., Ohlrogge A.W., Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 2018;138:271–281. doi: 10.1016/j.diabres.2018.02.023.
    1. Zheng Y., Ley S.H., Hu F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 2018;14:88–98. doi: 10.1038/nrendo.2017.151.
    1. Einarson T.R., Acs A., Ludwig C., Panton U.H. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc. Diabetol. 2018;17:83. doi: 10.1186/s12933-018-0728-6.
    1. McBride H.M., Neuspiel M., Wasiak S. Mitochondria: More than just a powerhouse. Curr. Biol. 2006;16:R551–R560. doi: 10.1016/j.cub.2006.06.054.
    1. Brehm A., Krssak M., Schmid A.I., Nowotny P., Waldhäusl W., Roden M. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes. 2006;55:136–140. doi: 10.2337/diabetes.55.01.06.db05-1286.
    1. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 2005;54:1615–1625. doi: 10.2337/diabetes.54.6.1615.
    1. Hernandez-Mijares A., Rocha M., Rovira-Llopis S., Banuls C., Bellod L., de Pablo C., Alvarez A., Roldan-Torres I., Sola-Izquierdo E., Victor V.M. Human leukocyte/endothelial cell interactions and mitochondrial dysfunction in type 2 diabetic patients and their association with silent myocardial ischemia. Diabetes Care. 2013;36:1695–1702. doi: 10.2337/dc12-1224.
    1. Rovira-Llopis S., Rocha M., Falcon R., de Pablo C., Alvarez A., Jover A., Hernandez-Mijares A., Victor V.M. Is myeloperoxidase a key component in the ROS-induced vascular damage related to nephropathy in type 2 diabetes? Antioxid. Redox Signal. 2013;19:1452–1458. doi: 10.1089/ars.2013.5307.
    1. Ahmed F.N., Naqvi F.N., Shafiq F. Lipid peroxidation and serum antioxidant enzymes in patients with type 2 diabetes mellitus. Ann. N.Y. Acad. Sci. 2006;1084:481–489. doi: 10.1196/annals.1372.022.
    1. Dandona P., Thusu K., Cook S., Snyder B., Makowski J., Armstrong D., Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet. 1996;347:444–445. doi: 10.1016/S0140-6736(96)90013-6.
    1. Al-Aubaidy H.A., Jelinek H.F. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur. J. Endocrinol. 2011;164:899–904. doi: 10.1530/EJE-11-0053.
    1. Whittaker R.G., Schaefer A.M., McFarland R., Taylor R.W., Walker M., Turnbull D.M. Prevalence and progression of diabetes in mitochondrial disease. Diabetologia. 2007;50:2085–2089. doi: 10.1007/s00125-007-0779-9.
    1. Al-Gadi I.S., Haas R.H., Falk M.J., Goldstein A., McCormack S.E. Endocrine Disorders in Primary Mitochondrial Disease. J. Endoc. Soc. 2018;2:361–373. doi: 10.1210/js.2017-00434.
    1. Chow J., Rahman J., Achermann J.C., Dattani M.T., Rahman S. Mitochondrial disease and endocrine dysfunction. Nat. Rev. Endocrinol. 2017;13:92–104. doi: 10.1038/nrendo.2016.151.
    1. Marroqui L., Tuduri E., Alonso-Magdalena P., Quesada I., Nadal A., Dos Santos R.S. Mitochondria as a target of endocrine-disrupting chemicals: Implications for type 2 diabetes. J. Endocrinol. 2018;239:R27–R45. doi: 10.1530/JOE-18-0362.
    1. Hayashi G., Cortopassi G. Oxidative stress in inherited mitochondrial diseases. Free Radic. Biol. Med. 2015;88:10–17. doi: 10.1016/j.freeradbiomed.2015.05.039.
    1. Di Meo S., Reed T.T., Venditti P., Victor V.M. Role of ROS and RNS Sources in Physiological and Pathological Conditions. Oxid. Med. Cell. Longev. 2016 doi: 10.1155/2016/1245049.
    1. Di Meo S., Reed T.T., Venditti P., Victor V.M. Harmful and Beneficial Role of ROS 2017. Oxid. Med. Cell Longev. 2018;2018:5943635. doi: 10.1155/2018/5943635.
    1. Mason P.A., Matheson E.C., Hall A.G., Lightowlers R.N. Mismatch repair activity in mammalian mitochondria. Nucleic Acids Res. 2003;31:1052–1058. doi: 10.1093/nar/gkg167.
    1. Szczepanowska K., Trifunovic A. Different faces of mitochondrial DNA mutators. Biochim. Biophys. Acta. 2015;1847:1362–1372. doi: 10.1016/j.bbabio.2015.05.016.
    1. Fetterman J.L., Holbrook M., Westbrook D.G., Brown J.A., Feeley K.P., Breton-Romero R., Linder E.A., Berk B.D., Weisbrod R.M., Widlansky M.E., et al. Mitochondrial DNA damage and vascular function in patients with diabetes mellitus and atherosclerotic cardiovascular disease. Cardiovasc. Diabetol. 2016;15:53. doi: 10.1186/s12933-016-0372-y.
    1. Rovira-Llopis S., Banuls C., Apostolova N., Morillas C., Hernandez-Mijares A., Rocha M., Victor V.M. Is glycemic control modulating endoplasmic reticulum stress in leukocytes of type 2 diabetic patients? Antioxid. Redox Signal. 2014;21:1759–1765. doi: 10.1089/ars.2014.6030.
    1. Papa F.R. Endoplasmic reticulum stress, pancreatic beta-cell degeneration, and diabetes. Cold Spring Harb. Perspect. Med. 2012;2:a007666 (epub). doi: 10.1101/cshperspect.a007666.
    1. Sun J., Cui J., He Q., Chen Z., Arvan P., Liu M. Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes. Mol. Aspects Med. 2015;42:105–118. doi: 10.1016/j.mam.2015.01.001.
    1. Zeeshan H.M., Lee G.H., Kim H.R., Chae H.J. Endoplasmic Reticulum Stress and Associated ROS. Int. J. Mol. Sci. 2016;17:327. doi: 10.3390/ijms17030327.
    1. Murphy M.P. Mitochondrial dysfunction indirectly elevates ROS production by the endoplasmic reticulum. Cell Metab. 2013;18:145–146. doi: 10.1016/j.cmet.2013.07.006.
    1. Malhotra J.D., Kaufman R.J. Endoplasmic reticulum stress and oxidative stress: A vicious cycle or a double edged sword? Antioxid. Redox Signal. 2007;9:227–2293. doi: 10.1089/ars.2007.1782.
    1. Malhotra J.D., Miao H., Zhang K., Wolfson A., Pennathur S., Pipe S.W., Kaufman R.J. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc. Natl. Acad. Sci. USA. 2008;105:18525–18530. doi: 10.1073/pnas.0809677105.
    1. Klusener B., Boheim G., Liss H., Engelberth J., Weiler E.W. Gadolinium-sensitive, voltage-dependent calcium release channels in the endoplasmic reticulum of a higher plant mechanoreceptor organ. EMBO J. 1995;14:2708–2714. doi: 10.1002/j.1460-2075.1995.tb07271.x.
    1. Gilroy S., Bialasek M., Suzuki N., Gorecka M., Devireddy A.R., Karpinski S., Mittler R. ROS, Calcium, and Electric Signals: Key Mediators of Rapid Systemic Signaling in Plants. Plant Physiol. 2016;171:1606–1615. doi: 10.1104/pp.16.00434.
    1. Sassano M.L., van Vliet A.R., Agostinis P. Mitochondria-Associated Membranes As Networking Platforms and Regulators of Cancer Cell Fate. Front. Oncol. 2017;7:174. doi: 10.3389/fonc.2017.00174.
    1. Gonzalez C.D., Lee M.S., Marchetti P., Pietropaolo M., Towns R., Vaccaro M.I., Watada H., Wiley J.W. The emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy. 2011;7:2–11. doi: 10.4161/auto.7.1.13044.
    1. Dodson M., Redmann M., Rajasekaran N.S., Darley-Usmar V., Zhang J. KEAP1- NRF2 signalling and autophagy in protection against oxidative and reductive proteotoxicity. Biochem. J. 2015;469:347–355. doi: 10.1042/BJ20150568.
    1. Scherz-Shouval R., Elazar Z. Regulation of autophagy by ROS: Physiology and pathology. Trends Biochem. Sci. 2011;36:30–38. doi: 10.1016/j.tibs.2010.07.007.
    1. Filomeni G., De Zio D., Cecconi F. Oxidative stress and autophagy: The clash between damage and metabolic needs. Cell Death Differ. 2015;22:377–388. doi: 10.1038/cdd.2014.150.
    1. Naito T., Kuma A., Mizushima N. Differential contribution of insulin and amino acids to the mTORC1-autophagy pathway in the liver and muscle. J. Biol. Chem. 2013;288:21074–21081. doi: 10.1074/jbc.M113.456228.
    1. Kruse R., Vind B.F., Petersson S.J., Kristensen J.M., Hojlund K. Markers of autophagy are adapted to hyperglycaemia in skeletal muscle in type 2 diabetes. Diabetologia. 2015;58:2087–2095. doi: 10.1007/s00125-015-3654-0.
    1. Monaco C.M.F., Hughes M.C., Ramos S.V., Varah N.E., Lamberz C., Rahman F.A., McGlory C., Tarnopolsky M.A., Krause M.P., Laham R., et al. Altered mitochondrial bioenergetics and ultrastructure in the skeletal muscle of young adults with type 1 diabetes. Diabetologia. 2018;61:1411–1423. doi: 10.1007/s00125-018-4602-6.
    1. Moller A.B., Kampmann U., Hedegaard J., Thorsen K., Nordentoft I., Vendelbo M.H., Moller N., Jessen N. Altered gene expression and repressed markers of autophagy in skeletal muscle of insulin resistant patients with type 2 diabetes. Sci. Rep. 2017;7:43775. doi: 10.1038/srep43775.
    1. Klionsky D.J., Abdelmohsen K., Abe A., Abedin M.J., Abeliovich H., Adachi H., Adams C.M., Adams P.D., Adeli K., Adhihetty P.J., et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Autophagy. 2016;12:1–222. doi: 10.1080/15548627.2015.1100356.
    1. Ost A., Svensson K., Ruishalme I., Brannmark C., Franck N., Krook H., Sandstrom P., Kjolhede P., Stralfors P. Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes. Mol. Med. 2010;16:235–246. doi: 10.2119/molmed.2010.00023.
    1. Kosacka J., Kern M., Klöting N., Paeschke S., Rudich A., Haim Y., Gericke M., Serke H., Stumvoll M., Bechmann I., et al. Autophagy in adipose tissue of patients with obesity and type 2 diabetes. Mol. Cell. Endocrinol. 2015;409:21–32. doi: 10.1016/j.mce.2015.03.015.
    1. Liu H.Y., Han J., Cao S.Y., Hong T., Zhuo D., Shi J., Liu Z., Cao W. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: Inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J. Biol. Chem. 2009;284:31484–31492. doi: 10.1074/jbc.M109.033936.
    1. Bhansali S., Bhansali A., Walia R., Saikia U.N., Dhawan V. Alterations in Mitochondrial Oxidative Stress and Mitophagy in Subjects with Prediabetes and Type 2 Diabetes Mellitus. Front. Endocrinol. 2017;8:347. doi: 10.3389/fendo.2017.00347.
    1. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Investig. 2003;112:1049–1057. doi: 10.1172/JCI18127.
    1. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010;107:1058–1070. doi: 10.1161/CIRCRESAHA.110.223545.
    1. Lenzen S., Drinkgern J., Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic. Biol. Med. 1996;20:463–466. doi: 10.1016/0891-5849(96)02051-5.
    1. Tiedge M., Lortz S., Drinkgern J., Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes. 1997;46:1733–1742. doi: 10.2337/diab.46.11.1733.
    1. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., Takahashi H. Glucose toxicity in beta-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581–587. doi: 10.2337/diabetes.52.3.581.
    1. Heimberg H., De Vos A., Vandercammen A., Van Schaftinger E., Pipeleers D., Schuit F. Heterogeneity in glucose sensitivity among pancreatic beta-cells is correlated to differences in glucose phosphorylation rather than glucose transport. EMBO J. 1993;12:2873–2879. doi: 10.1002/j.1460-2075.1993.tb05949.x.
    1. Sekine N., Cirulli V., Regazzi R., Brown L.J., Gine E., Tamarit-Rodriguez J., Girotti M., Marie S., MacDonald M.J., Wollheim C.B., et al. Low lactate dehydrogenase and high mitochondrial glycerol phosphate dehydrogenase in pancreatic beta-cells. Potential role in nutrient sensing. J. Biol. Chem. 1994;269:4895–4902.
    1. Henderson J.R., Moss M.C. A morphometric study of the endocrine and exocrine capillaries of the pancreas. Q. J. Exp. Physiol. 1985;70:347–356. doi: 10.1113/expphysiol.1985.sp002920.
    1. In't Veld P., Marichal M. Microscopic anatomy of the human islet of Langerhans. Adv. Exp. Med. Biol. 2010;654:1–19. doi: 10.1007/978-90-481-3271-3_1.
    1. Thorens B. Molecular and cellular physiology of GLUT-2, a high-Km facilitated diffusion glucose transporter. Int. Rev. Cytol. 1992;137:209–238.
    1. Cao S.S., Kaufman R.J. Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid. Redox Signal. 2014;21:396–413. doi: 10.1089/ars.2014.5851.
    1. Rubinsztein D.C., Frake R.A. Yoshinori Ohsumi’s Nobel Prize for mechanisms of autophagy: From basic yeast biology to therapeutic potential. J. R. Coll. Physicians Edinb. 2016;46:228–233. doi: 10.4997/JRCPE.2016.303.
    1. Levine B., Klionsky D.J. Autophagy wins the 2016 Nobel Prize in Physiology or Medicine: Breakthroughs in baker's yeast fuel advances in biomedical research. Proc. Natl. Acad. Sci. USA. 2017;114:201–205. doi: 10.1073/pnas.1619876114.
    1. Marasco M.R., Linnemann A.K. β-Cell Autophagy in Diabetes Pathogenesis. Endocrinology. 2018;159:2127–2141. doi: 10.1210/en.2017-03273.
    1. Kim J., Lim Y.M., Lee M.S. The Role of Autophagy in Systemic Metabolism and Human-Type Diabetes. Mol. Cells. 2018;41:11–17. doi: 10.14348/molcells.2018.2228.
    1. Hayes H.L., Peterson B.S., Haldeman J.M., Newgard C.B., Hohmeier H.E., Stephens S.B. Delayed apoptosis allows islet beta-cells to implement an autophagic mechanism to promote cell survival. PLoS ONE. 2017;12:e0172567. doi: 10.1371/journal.pone.0172567.
    1. Kroemer G., Marino G., Levine B. Autophagy and the integrated stress response. Mol. Cell. 2010;40:280–293. doi: 10.1016/j.molcel.2010.09.023.
    1. Ahmed A.E., Kirova D., Konantz J., Birke S., Mansfeld J., Ninov N. Distinct Levels of Reactive Oxygen Species Coordinate Metabolic Activity with Beta-cell Mass Plasticity. Sci. Rep. 2017;7:3994. doi: 10.1038/s41598-017-03873-9.
    1. Kaiser N., Sasson S., Feener E.P., Boukobza-Vardi N., Higashi S., Moller D.E., Davidheiser S., Przybylski R.J., King G.L. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes. 1993;42:80–89. doi: 10.2337/diab.42.1.80.
    1. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation. 2006;114:597–605. doi: 10.1161/CIRCULATIONAHA.106.621854.
    1. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., Tordo P., Pritchard K.A. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc. Nati. Acad. Sci. USA. 1998;95:9220–9225. doi: 10.1073/pnas.95.16.9220.
    1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820. doi: 10.1038/414813a.
    1. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007;87:245–313. doi: 10.1152/physrev.00044.2005.
    1. San M.A., Du P., Dikalova A., Lassegue B., Aleman M., Gongora M.C., Brown K., Joseph G., Harrison D.G., Taylor W.R., et al. Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 2007;292:H2073–H2082. doi: 10.1152/ajpheart.00943.2006.
    1. Gao L., Mann G.E. Vascular NAD(P)H oxidase activation in diabetes: A double-edged sword in redox signalling. Cardiovasc. Res. 2009;82:9–20. doi: 10.1093/cvr/cvp031.
    1. Zhu L., He P. fMLP-stimulated release of reactive oxygen species from adherent leukocytes increases microvessel permeability. Am. J. Physiol. Heart Circ. Physiol. 2006;290:H365–H372. doi: 10.1152/ajpheart.00812.2005.
    1. Lavrovsky Y., Chatterjee B., Clark R.A., Roy A.K. Role of redox-regulated transcription factors in inflammation, aging and age-related diseases. Exp. Gerontol. 2000;35:521–532. doi: 10.1016/S0531-5565(00)00118-2.
    1. Gonzalez L.L., Garrie K., Turner M.D. Type 2 diabetes—An autoinflammatory disease driven by metabolic stress. Biochim Biophys Acta Mol Basis Dis. 2018;1864:3805–3823. doi: 10.1016/j.bbadis.2018.08.034.
    1. Ehses J.A., Perren A., Eppler E., Ribaux P., Pospisilik J.A., Maor-Cahn R., Gueripel X., Ellingsgaard H., Schneider M.K., Biollaz G., et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007;56:2356–2370. doi: 10.2337/db06-1650.
    1. Böni-Schnetzler M., Ehses J.A., Faulenbach M., Donath M.Y. Insulitis in type 2 diabetes. Diabetes Obes. Metab. 2008;10:201–204. doi: 10.1111/j.1463-1326.2008.00950.x.
    1. Choudhury S., Ghosh S., Gupta P., Mukherjee S., Chattopadhyay S. Inflammation-induced ROS generation causes pancreatic cell death through modulation of Nrf2/NF-kappaB and SAPK/JNK pathway. Free Rad. Res. 2015;49:1371–1383. doi: 10.3109/10715762.2015.1075016.
    1. Dinesh Shah A., Langenberg C., Rapsomaniki E., Denaxas S., Pujades-Rodriguez M., Gale C.P., Deanfield J., Smeeth L., Timmis A., Hemingway H. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: A cohort study in 1.9 million people. Lancet. 2015;385:S86. doi: 10.1016/S0140-6736(15)60401-9.
    1. Weinberg J.M. Lipotoxicity. Kidney Int. 2006;70:1560–1566. doi: 10.1038/sj.ki.5001834.
    1. Tumova J., Andel M., Trnka J. Excess of free fatty acids as a cause of metabolic dysfunction in skeletal muscle. Physiol. Res. 2016;65:193–207.
    1. Palomer X., Pizarro-Delgado J., Barroso E., Vazquez-Carrera M. Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus. Trends Endocrinol. Metab. 2018;29:178–190. doi: 10.1016/j.tem.2017.11.009.
    1. Oh Y.S., Bae G.D., Baek D.J., Park E.Y., Jun H.S. Fatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells During Development of Type 2 Diabetes. Front. Endocrinol. 2018;9:384. doi: 10.3389/fendo.2018.00384.
    1. Sharma R.B., Alonso L.C. Lipotoxicity in the pancreatic beta cell: Not just survival and function, but proliferation as well. Curr. Diab. Rep. 2014;14:492. doi: 10.1007/s11892-014-0492-2.
    1. Poitout V., Robertson R.B. Glucolipotoxicity: Fuel excess and beta-cell dysfunction. Endocr. Rev. 2008;29:351–366. doi: 10.1210/er.2007-0023.
    1. Prentki M., Matschinsky F.M., Madiraju S.R. Metabolic signaling in fuel-induced insulin secretion. Cell Metab. 2013;18:162–185. doi: 10.1016/j.cmet.2013.05.018.
    1. Forouhi N.G., Misra A., Mohan V., Taylor R., Yancy W. Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ. 2018;361:k2234. doi: 10.1136/bmj.k2234.
    1. Langhans W. Food Components in Health Promotion and Disease Prevention. J. Agric. Food Chem. 2018;66:2287–2294. doi: 10.1021/acs.jafc.7b02121.
    1. Ceriello A., Esposito K., La Sala L., Pujadas G., De Nigris V., Testa R., Bucciarelli L., Rondinelli M., Genovese S. The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: A preliminary report. Cardiovasc. Diabetol. 2014;13:140. doi: 10.1186/s12933-014-0140-9.
    1. Cooper A.J., Sharp S.J., Luben R.N., Khaw K.T., Wareham N.J., Forouhi N.G. The association between a biomarker score for fruit and vegetable intake and incident type 2 diabetes: The EPIC-Norfolk study. Eur. J. Clin. Nutr. 2015;69:449–454. doi: 10.1038/ejcn.2014.246.
    1. Fagherazzi G., Gusto G., Mancini F.R., Dow C., Rajaobelina K., Balkau B., Boutron-Ruault M.C., Bonnet F. Determinants of 20-year non-progression to Type 2 diabetes in women at very high risk: The E3N cohort study. Diabet. Med. 2018;35:1716–1721. doi: 10.1111/dme.13774.
    1. Cory H., Passarelli S., Szeto J., Tamez M., Mattei J. The Role of Polyphenols in Human Health and Food Systems: A Mini-Review. Front. Nutr. 2018;5:87. doi: 10.3389/fnut.2018.00087.
    1. Cripps M.J., Hanna K., Lavilla C., Jr., Sayers S.R., Caton P.W., Sims C., De Girolamo L., Sale C., Turner M.D. Carnosine scavenging of glucolipotoxic free radicals enhances insulin secretion and glucose uptake. Sci. Rep. 2017;17:13313. doi: 10.1038/s41598-017-13649-w.
    1. Houjeghani S., Kheirouri S., Faraji E., Jafarabadi M.A. l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: A double-blind placebo-controlled randomized clinical trial. Nutr. Res. 2018;49:96–106. doi: 10.1016/j.nutres.2017.11.003.
    1. Karkabounas S., Papadopoulos N., Anastasiadou C., Gubili C., Peschos D., Daskalou T., Fikioris N., Simos Y.V., Kontargiris E., Gianakopoulos X., et al. Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study. J. Med. Food. 2018;21:1197–1203. doi: 10.1089/jmf.2018.0007.
    1. Elbarbary N.S., Ismail E.A.R., El-Naggar A.R., Hamouda M.H., El-Hamamsy M. The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: A randomized placebo-controlled trial. Pediatric Diabetes. 2018;19:470–477. doi: 10.1111/pedi.12564.
    1. Testa R., Bonfigli A.R., Genovese S., De Nigris V., Ceriello A. The Possible Role of Flavonoids in the Prevention of Diabetic Complications. Nutrients. 2016;8:310. doi: 10.3390/nu8050310.
    1. Putta S., Yarla N.S., Kumar K.E., Lakkappa D.B., Kamal M.A., Scotti L., Scotti M.T., Ashraf G.M., Rao B.S.D., SK D., et al. Preventive and Therapeutic Potentials of Anthocyanins in Diabetes and Associated Complications. Curr. Med. Chem. 2018;25:5347–5371. doi: 10.2174/0929867325666171206101945.
    1. Munir M.R., Chandrasekaran S., Gao F., Quon M.J. Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: Therapeutic implications for diabetes and its cardiovascular complications. Am. J. Physiol. Endocrinol. Metab. 2013;305:E679–E686. doi: 10.1152/ajpendo.00377.2013.
    1. Pietta P.G. Flavonoids as antioxidants. J. Nat. Prod. 2000;63:1035–1042. doi: 10.1021/np9904509.
    1. Oboh G., Agunloye O.M., Adefegha S.A., Akinyemi A.J., Ademiluyi A.O. Caffeic and chlorogenic acids inhibit key enzymes linked to type 2 diabetes (in vitro): A comparative study. J. Basic Clin. Physiol. Pharmacol. 2015;26:165–170. doi: 10.1515/jbcpp-2013-0141.
    1. Calderon-Montano J.M., Burgos-Moron E., Perez-Guerrero C., Lopez-Lazaro M. A review on the dietary flavonoid kaempferol. Mini Rev. Med. Chem. 2011;11:298–344. doi: 10.2174/138955711795305335.
    1. Ghosh S., Chowdhury S., Sarkar P., Sil P.C. Ameliorative role of ferulic acid against diabetes associated oxidative stress induced spleen damage. Food Chem. Toxicol. 2018;118:272–286. doi: 10.1016/j.fct.2018.05.029.
    1. Jin T.R. Curcumin and dietary polyphenol research: Beyond drug discovery. Acta Pharmacol. Sin. 2018;39:779–786. doi: 10.1038/aps.2017.179.
    1. Aloud A.A., Veeramani C., Govindasamy C., Alsaif M.A., Al-Numair K.S. Galangin, a natural flavonoid reduces mitochondrial oxidative damage in streptozotocin-induced diabetic rats. Redox Rep. 2018;23:29–34. doi: 10.1080/13510002.2017.1365224.
    1. Tsuchiya T., Endo A., Tsujikado K., Inukai T. Involvement of Resveratrol and omega-3 Polyunsaturated Fatty Acids on Sirtuin 1 Gene Expression in THP1 Cells. Am. J. Med. Sci. 2017;354:415–422. doi: 10.1016/j.amjms.2017.06.002.
    1. Zendedel E., Butler A.E., Atkin S.L., Sahebkar A. Impact of curcumin on sirtuins: A review. J. Cell. Biochem. 2018;119:10291–10300. doi: 10.1002/jcb.27371.
    1. Sarkar P., Bhowmick A., Kalita M.C., Banu S. Effects of Resveratrol and Mangiferin on PPARγ and FALDH Gene Expressions in Adipose Tissue of Streptozotocin-Nicotinamide-Induced Diabetes in Rats. J. Diet. Suppl. 2018;1:1–17. doi: 10.1080/19390211.2018.1472714.
    1. Öztürk E., Arslan A.K.K., Yerer M.B., Bishayee A. Resveratrol and diabetes: A critical review of clinical studies. Biomed. Pharmacother. 2017;95:230–234. doi: 10.1016/j.biopha.2017.08.070.
    1. Cao M.M., Lu X., Liu G.D., Su Y., Li Y.B., Zhou J. Resveratrol attenuates type 2 diabetes mellitus by mediating mitochondrial biogenesis and lipid metabolism via Sirtuin type 1. Exp. Ther. Med. 2018;15:576–584. doi: 10.3892/etm.2017.5400.
    1. Oyenihi O.R., Oyenihi A.B., Adeyanju A.A., Oguntibeju O.O. Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility. J. Diabetes Res. 2016;2016:9737483. doi: 10.1155/2016/9737483.
    1. Balbi M.E., Tonin F.S., Mendes A.M., Borba H.H., Wiens A., Fernandez-Llimos F., Pontarolo R. Antioxidant effects of vitamins in type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetol. Metab. Syndr. 2018;10:18. doi: 10.1186/s13098-018-0318-5.
    1. Montero D., Walther G., Stehouwer C.D., Houben A.J., Beckman J.A., Vinet A. Effect of antioxidant vitamin supplementation on endothelial function in type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Obes. Rev. 2014;15:107–116. doi: 10.1111/obr.12114.
    1. Bolignano D., Cernaro V., Gembillo G., Baggetta R., Buemi M., D'Arrigo G. Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis. PLoS ONE. 2017;12:e0178699. doi: 10.1371/journal.pone.0178699.
    1. Rodriguez-Carrizalez A.D. Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy. [(accessed on 26 March 2019)]; Available online: ; .
    1. Hoggard N. Study of Oral Anthocyanins on Insulin Resistance. [(accessed on 26 March 2019)]; Available online: ; .
    1. Gordillo G.M. Effects of Capros in Patients with Type-1 Diabetes (CarposT1D) [(accessed on 26 March 2019)]; Available online: ; .
    1. Mohamed S.A., El-Shishtawy R.M., Al-Bar O.A.M., Al-Najada A.R. Chemical modification of curcumin: Solubility and antioxidant capacity. Int. J. Food Prop. 2016;20:718–724. doi: 10.1080/10942912.2016.1177545.
    1. Sun B., Wang W., He Z., Zhang M., Kong F., Sain M., Ni Y. Improvement of Stability of Tea Polyphenols: A Review. Curr. Pharm. Des. 2018;24:3410–3423. doi: 10.2174/1381612824666180810160321.
    1. Nankar R., Prabhakar P.K., Doble M. Hybrid drug combination: Combination of ferulic acid and metformin as anti-diabetic therapy. Phytomedicine. 2017;37:10–13. doi: 10.1016/j.phymed.2017.10.015.
    1. Girnun G.D., Domann F.E., Moore S.A., Robbins M.E. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol. Endocrinol. 2002;16:2793–2801. doi: 10.1210/me.2002-0020.
    1. Inoue I., Goto S., Matsunaga T., Nakajima T., Awata T., Hokari S., Komoda T., Katayama S. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001;50:3–11. doi: 10.1053/meta.2001.19415.
    1. Khoo N.K., Hebbar S., Zhao W., Moore S.A., Domann F.E., Robbins M.E. Differential activation of catalase expression and activity by PPAR agonists: Implications for astrocyte protection in anti-glioma therapy. Redox Biol. 2013;1:70–79. doi: 10.1016/j.redox.2012.12.006.
    1. Da Ros R., Assaloni R., Ceriello A. The preventive anti-oxidant action of thiazolidinediones: A new therapeutic prospect in diabetes and insulin resistance. Diabet. Med. 2004;21:1249–1252. doi: 10.1111/j.1464-5491.2004.01312.x.
    1. O'Brien R.C., Luo M., Balazs N., Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J. Diabetes Complicat. 2000;14:201–206. doi: 10.1016/S1056-8727(00)00084-2.
    1. McGavin J.K., Perry C.M., Goa K.L. Gliclazide modified release. Drugs. 2002;62:1357–1364. doi: 10.2165/00003495-200262090-00010.
    1. Cameron A.R., Logie L., Patel K., Erhardt S., Bacon S., Middleton P., Harthill J., Forteath C., Coats J.T., Kerr C., et al. Metformin selectively targets redox control of complex I energy transduction. Redox Biol. 2018;14:187–197. doi: 10.1016/j.redox.2017.08.018.
    1. Wu J., Luo X., Thangthaeng N., Sumien N., Chen Z., Rutledge M.A., Jing S., Forster M.J., Yan L.J. Pancreatic mitochondrial complex I exhibits aberrant hyperactivity in diabetes. Biochem. Biophys. Rep. 2017;11:119–129. doi: 10.1016/j.bbrep.2017.07.007.
    1. Batchuluun B., Inoguchi T., Sonoda N., Sasaki S., Inoue T., Fujimura Y., Miura D., Takayanagi R. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis. 2014;232:156–164. doi: 10.1016/j.atherosclerosis.2013.10.025.
    1. Bridges H.R., Jones A.J., Pollak M.N., Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 2014;462:475–487. doi: 10.1042/BJ20140620.
    1. Bridges H.R., Sirvio V.A., Agip A.N., Hirst J. Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase. BMC Biol. 2016;14:65. doi: 10.1186/s12915-016-0287-9.
    1. Moon J.S., Karunakaran U., Elumalai S., Lee I.K., Lee H.W., Kim Y.W., Won K.C. Metformin prevents glucotoxicity by alleviating oxidative and ER stress-induced CD36 expression in pancreatic beta cells. J. Diabetes Complicat. 2017;31:21–30. doi: 10.1016/j.jdiacomp.2016.09.001.
    1. Sambe T., Mason R.P., Dawoud H., Bhatt D.L., Malinski T. Metformin treatment decreases nitroxidative stress, restores nitric oxide bioavailability and endothelial function beyond glucose control. Biomed. Pharm. 2018;98:149–156. doi: 10.1016/j.biopha.2017.12.023.
    1. Ceriello A., Novials A., Ortega E., Canivell S., La Sala L., Pujadas G., Esposito K., Giugliano D., Genovese S. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013;36:2346–2350. doi: 10.2337/dc12-2469.
    1. Oeseburg H., de Boer R.A., Buikema H., van der Harst P., van Gilst W.H., Silljé H. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler. Thromb. Vasc. Biol. 2010;30:1407–1414. doi: 10.1161/ATVBAHA.110.206425.
    1. Oh Y.S., Jun H.S. Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling. Int. J. Mol. Sci. 2017;19:26. doi: 10.3390/ijms19010026.
    1. Spencer N.Y., Yang Z., Sullivan J.C., Klein T., Stanton R.C. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes. PLoS ONE. 2018;13:e0200249. doi: 10.1371/journal.pone.0200249.
    1. Civantos E., Bosch E., Ramirez E., Zhenyukh O., Egido J., Lorenzo O., Mas S. Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway. Diabetes Metab. Syndr. Obes. 2017;10:207–222. doi: 10.2147/DMSO.S132537.
    1. Bao W., Morimoto K., Hasegawa T., Sasaki N., Yamashita T., Hirata K., Okita Y., Okada K. Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats. J. Vasc. Surg. 2014;59:1098–1108. doi: 10.1016/j.jvs.2013.04.048.
    1. Pujadas G., De Nigris V., Prattichizzo F., La Sala L., Testa R., Ceriello A. The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Endocrine. 2017;56:509–520. doi: 10.1007/s12020-016-1052-0.
    1. Dandona P., Ghanim H., Abuaysheh S., Green K., Dhindsa S., Makdissi A., Batra M., Kuhadiya N.D., Chaudhuri A. Exenatide Increases IL-1RA Concentration and Induces Nrf-2Keap-1Regulated Antioxidant Enzymes: Relevance to beta-Cell Function. J. Clin. Endocrin. Metab. 2018;103:1180–1187. doi: 10.1210/jc.2017-02343.
    1. Deng C., Cao J., Han J., Li J., Li Z., Shi N., He J. Liraglutide Activates the Nrf2/HO-1 Antioxidant Pathway and Protects Brain Nerve Cells against Cerebral Ischemia in Diabetic Rats. Comput. Intell. Neurosci. 2018;2018:3094504. doi: 10.1155/2018/3094504.
    1. Guo J., Li C., Yang C., Li B., Wei J., Lin Y., Ye P., Hu G., Li J. Liraglutide reduces hepatic glucolipotoxicity-induced liver cell apoptosis through NRF2 signaling in Zucker diabetic fatty rats. Mol. Med. Rep. 2018;17:8316–8324. doi: 10.3892/mmr.2018.8919.
    1. Yu J., Morimoto K., Bao W., Yu Z., Okita Y., Okada K. Glucagon-like peptide-1 prevented abdominal aortic aneurysm development in rats. Surg. Today. 2016;46:1099–1107. doi: 10.1007/s00595-015-1287-z.
    1. Apostolova N., Victor V.M. Molecular strategies for targeting antioxidants to mitochondria: Therapeutic implications. Antiox. Redox Signal. 2015;22:686–729. doi: 10.1089/ars.2014.5952.
    1. Wen R., Banik B., Pathak R.K., Kumar A., Kolishetti N., Dhar S. Nanotechnology inspired tools for mitochondrial dysfunction related diseases. Adv. Drug Deliv. Rev. 2016;99:52–69. doi: 10.1016/j.addr.2015.12.024.
    1. Escribano-Lopez I., Diaz-Morales N., Rovira-Llopis S., Martínez de Maranón A., Orden S., Alvarez A., Banuls C., Rocha M., Murphy M.P., Hernandez-Mijares A., et al. The mitochondria-targeted antioxidant MitoQ modulates oxidative stress, inflammation and leukocyte-endothelium interactions in leukocytes isolated from type 2 diabetic patients. Redox Biol. 2016;10:200–205. doi: 10.1016/j.redox.2016.10.017.
    1. Gupta P., Jordan C.T., Mitov M.I., Butterfield D.A., Hilt J.Z., Dziubla T.D. Controlled curcumin release via conjugation into PBAE nanogels enhances mitochondrial protection against oxidative stress. Int. J. Pharm. 2016;511:1012–1021. doi: 10.1016/j.ijpharm.2016.07.071.
    1. Yucel C., Karatoprak G.S., Aktas Y. Nanoliposomal Resveratrol as a Novel Approach to Treatment of Diabetes Mellitus. J. Nanosci. Nanotechnol. 2018;18:3856–3864. doi: 10.1166/jnn.2018.15247.
    1. Saleh T., Soudi T., Shojaosadati S.A. Redox responsive curcumin-loaded human serum albumin nanoparticles: Preparation, characterization and in vitro evaluation. Int. J. Biol. Macromol. 2018;114:759–766. doi: 10.1016/j.ijbiomac.2018.03.085.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe